BLFS logo

BioLife Solutions, Inc. Stock Price

NasdaqCM:BLFS Community·US$1.3b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 7 Fair Values set on narratives written by author

BLFS Share Price Performance

US$26.80
3.36 (14.33%)
14.4% undervalued intrinsic discount
US$31.30
Fair Value
US$26.80
3.36 (14.33%)
14.0% undervalued intrinsic discount
US$31.16
Fair Value
Price US$26.80
AnalystConsensusTarget US$31.16

BLFS Community Narratives

AnalystConsensusTarget·
Fair Value US$31.3 12.7% undervalued intrinsic discount

Cell And Gene Therapies Will Unlock Biopreservation Potential

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative

Recent BLFS News & Updates

BioLife Solutions: Back To Basics Is Getting Traction (Rating Upgrade)

Oct 01

BioLife Solutions, Inc.'s (NASDAQ:BLFS) P/S Is Still On The Mark Following 25% Share Price Bounce

Sep 06
BioLife Solutions, Inc.'s (NASDAQ:BLFS) P/S Is Still On The Mark Following 25% Share Price Bounce

Is BioLife Solutions (NASDAQ:BLFS) A Risky Investment?

Aug 09
Is BioLife Solutions (NASDAQ:BLFS) A Risky Investment?

Investors Still Waiting For A Pull Back In BioLife Solutions, Inc. (NASDAQ:BLFS)

Jul 04
Investors Still Waiting For A Pull Back In BioLife Solutions, Inc. (NASDAQ:BLFS)

BioLife Solutions, Inc. Key Details

US$93.5m

Revenue

US$33.0m

Cost of Revenue

US$60.4m

Gross Profit

US$79.4m

Other Expenses

-US$18.9m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
-0.39
Gross Margin
64.67%
Net Profit Margin
-20.24%
Debt/Equity Ratio
2.9%

BioLife Solutions, Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Excellent balance sheet with reasonable growth potential.

1 Risk
2 Rewards

About BLFS

Founded
1987
Employees
159
CEO
Roderick de Greef
WebsiteView website
www.biolifesolutions.com

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

U.S. Market Performance

  • 7 Days: -2.7%
  • 3 Months: 5.1%
  • 1 Year: 13.4%
  • Year to Date: 11.7%
Over the last 7 days, the market has dropped 2.7%, driven by a loss of 2.5% in the Information Technology sector. As for the longer term, the market has actually risen by 13% in the last year. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›